Pasquereau-Kotula Ewa, Hosten Benoit, Hontonnou Fortune, Vignal Nicolas, Antoni Florent, Poyet Jean-Luc, Rizzo-Padoin Nathalie, Sarda-Mantel Laure
Inserm UMR-S1160, Institut Universitaire d'Hématologie, Hôpital St-Louis Paris, France.
Unité Claude Kellershohn, Institut Universitaire d'Hématologie, Hôpital St-Louis Paris, France.
Am J Nucl Med Mol Imaging. 2018 Dec 20;8(6):397-406. eCollection 2018.
Bioluminescence imaging (BLI) is widely used for monitoring of anti-cancer therapy in mice. [F]MEL050 is a Positron Emission Tomography (PET) radiotracer which specifically targets melanin. We evaluated planar BLI and [F]MEL050-PET/CT for therapy (pro-apoptotic peptide LZDP) monitoring in a mouse model of metastatic pigmented melanoma. Twelve B6-albino mice were intravenously injected with B16-F10-luc2 cells on day 0 (D0). The mice received daily from D2 to D17 either an inactive peptide (G1, n=6), or LZDP (G2, n=6). They underwent both BLI and [F]MEL050-PET/CT imaging on D2, D8 and D17. The number of visible tumors was determined on BLI and PET/CT. [F]MEL050 uptake in tumor sites was quantified on PET/CT. After sacrifice (D17), the number of black tumors was counted . On D2, BLI and PET/CT images were visually negative. On D8, BLI detected 8 tumor sites in 4/6 mice of G1 vs 5 in 3/6 mice of G2 (NS); PET/CT was visually negative. On D17, BLI detected 17 tumor sites in 5/6 mice of G1 vs 10 in 4/6 mice of G2 (NS). PET/CT detected 18 tumor sites in 4/4 mice of G1 vs 14 in 3/4 mice of G2 (NS). Mean %ID/g of [F]MEL050 in tumor sites was lower in G2 than in G1 on D17 (P<0.001), whereas bioluminescence intensity was not different between the 2 groups. examination confirmed lower number of tumors in G2 (P<0.03). In the small number of animals tested in this study, [F]MEL050-PET/CT and examination could affirm anti-tumoral effect of LZDP, but not BLI.
生物发光成像（BLI）被广泛用于监测小鼠体内的抗癌治疗。[F]MEL050是一种正电子发射断层扫描（PET）放射性示踪剂，它特异性靶向黑色素。我们在转移性色素性黑色素瘤小鼠模型中评估了平面BLI和[F]MEL050-PET/CT用于治疗（促凋亡肽LZDP）监测的效果。12只B6白化小鼠在第0天（D0）静脉注射B16-F10-luc2细胞。从第2天到第17天，小鼠每天接受一种无活性肽（G1组，n = 6）或LZDP（G2组，n = 6）。它们在第2天、第8天和第17天接受了BLI和[F]MEL050-PET/CT成像。在BLI和PET/CT上确定可见肿瘤的数量。在PET/CT上对肿瘤部位的[F]MEL050摄取进行定量。处死（第17天）后，计数黑色肿瘤的数量。在第2天，BLI和PET/CT图像肉眼观察为阴性。在第8天，BLI在G1组的4/6只小鼠中检测到8个肿瘤部位，在G2组的3/6只小鼠中检测到5个肿瘤部位（无显著性差异）；PET/CT肉眼观察为阴性。在第17天，BLI在G1组的5/6只小鼠中检测到17个肿瘤部位，在G2组的4/6只小鼠中检测到10个肿瘤部位（无显著性差异）。PET/CT在G1组的4/4只小鼠中检测到18个肿瘤部位，在G2组的3/4只小鼠中检测到14个肿瘤部位（无显著性差异）。在第17天，G2组肿瘤部位的[F]MEL050平均%ID/g低于G1组（P<0.001），而两组之间的生物发光强度没有差异。尸检证实G2组的肿瘤数量较少（P<0.03）。在本研究中测试的少数动物中，[F]MEL050-PET/CT和尸检可以证实LZDP的抗肿瘤作用，但BLI不能。
